

SWISSWELL KNEE PATCH™ REGISTERED AS A MEDICAL DEVICE IN AUSTRALIA

Wellfully Limited (ASX: WFL) (Wellfully or the Company) is pleased to announce that the Swisswell Knee Patch™ has been successfully registered as a medical device in Australia, effective August 2nd, 2022.

- **The Swisswell Knee Patch has been registered with the TGA as a medical device in Australia**
- **The Australian topical pain relief market is valued at US\$ 725 million***
- **Registration as a medical device enables substantiated medical claims to be made, significantly broadening roll-out opportunities beyond just pharmacy partners across Australia**

The Swisswell Knee Patch™ was first test-launched in August 2021, but only sold through the Company's DTC (direct-to-consumer) channels as an unregistered medical device without any medical claims. Initial feedback from consumers, as well as interest from potential distribution partners, has been most positive.



With this registration, Wellfully is now able to freely engage with retail partners and specialist distributors in the Australian market, enabling a broad scale marketing effort that can include substantiated medical claims.

* OTC Pain Medication Manufacturing in Australia - Market Size 2007–2028, IBIS World, May 2022,

Director

Mr Paul Peros
Mr Steven Schapera
Mr Jeffrey Edwards
Mr Anton Eaton

CFO

Mr Sergej Dolezil

Company Secretary

Mr Henko Vos

Registered Office

284 Oxford Street
Leederville
Western Australia
6007

Contact

Tel: +61 8 9443 3011
www.wellfully.net
ABN: 72 056 482 636

ABOUT WELLFULLY

Wellfully is a fully integrated, science-based wellness company. In addition to our own-brands, RÉDUIT and SWISSWELL, we also offer a portfolio of proprietary technologies and support partners by providing IP and expertise in magnetic array design, feasibility and efficacy, claims testing, engineering, and production.

ABOUT WELLFULLY'S TECHNOLOGIES

Wellfully has developed a number of physical enhancement technologies based on the interactions between ingredient molecules and weak atomic forces, positioning the Company as a world leader in the science of magnetic fields as they relate to drug or active-ingredient delivery.

The first of Wellfully's magnetic technologies was the Magnetic Microarray. Complex 3-D magnetic fields, produced by low-cost microarray film, influence the movement and penetration through the skin of drugs, active ingredients, and formulations at the molecular level. This was licensed and commercialised in 2014.

The second magnetic technology, the Programmable Array technology, employs powered electromagnetic fields that can be altered to suit individual consumer's skincare needs. This was licensed for skincare applications in 2020.

The third magnetic technology uses magnetic fields to alter the wettability of a surface, substantially enhancing contact between liquid and solids. Magneto-Wetting underpins the Company's current developments in haircare, skincare, and surface hygiene, in conjunction with Wellfully's recently developed Ultrasonic Misting technology. International patents have been filed.

FORWARD-LOOKING STATEMENTS

This announcement contains certain "forward-looking statements" concerning Wellfully. Where Wellfully expresses or implies an expectation or belief as to future events or results, such expectation or belief is expressed in good faith and believed to have a reasonable basis.

Forward-looking statements provided in this announcement are based on assumptions and contingencies which are subject to change without notice. Such forward-looking

Director

Mr Paul Peros
Mr Steven Schapera
Mr Jeffrey Edwards
Mr Anton Eaton

CFO

Mr Sergej Dolezil

Company Secretary

Mr Henko Vos

Registered Office

284 Oxford Street
Leederville
Western Australia
6007

Contact

Tel: +61 8 9443 3011
www.wellfully.net
ABN: 72 056 482 636

statements including statements regarding intentions, planned events and potential results are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance.

There can be no assurance that actual outcomes will not differ materially from these forward-looking statements, and there are risks associated with Wellfully and the industry which may affect the accuracy of the forward-looking statements. Wellfully does not undertake any obligation to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date of this announcement or to reflect the occurrence of unanticipated events, except as may be required under applicable securities laws.

This release has been issued with the authorisation of the Board.

- Ends -

For more information:

Kira Bradbury

Advisir

Email: kira.bradbury@advisir.com.au

Phone: +61 405 928 128

Director

Mr Paul Peros
Mr Steven Schapera
Mr Jeffrey Edwards
Mr Anton Eaton

CFO

Mr Sergej Dolezil

Company Secretary

Mr Henko Vos

Registered Office

284 Oxford Street
Leederville
Western Australia
6007

Contact

Tel: +61 8 9443 3011
www.wellfully.net
ABN: 72 056 482 636